Treatment of severe or resistant corticosteroid-responsive dermatoses with Diprolene cream.
In an open study Diprolene Cream was administered to fifty patients with severe or resistant psoriasis, atopic dermatitis or other corticosteroid-responsive dermatoses. For a period of 14 days, patients applied 3.5 grams of medication twice daily. Efficacy was evaluated in forty-six patients, while tolerance and safety were evaluated in fifty patients. Therapeutic response in forty-one of forty-six patients was noted by treatment Day 3. By Day 14, mean total severity score of signs and symptoms in twenty-one patients with psoriasis was reduced by 88%. Similarly, in twenty-five patients with other severe or resistant corticosteroid-responsive dermatoses, a 99% decrease in the mean total severity score of signs and symptoms was evident. Of the patients evaluable for tolerance and safety, twenty-four of fifty reported transient, mild to moderate burning that occurred most often upon application of the study preparation. Therapy was not discontinued in any of these patients, and none required additional treatment for the local reaction. Morning plasma cortisol levels in monitored patients remained within normal limits throughout the study.
D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011409:Propylene Glycols; D011565:Psoriasis / Q000188:drug therapy*; D012871:Skin Diseases / Q000188:drug therapy*
D009824:Ointments; D011409:Propylene Glycols; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone